T-Cell Immunotherapy for Cancer Pipeline Market Analysis Report T-Cell Immunotherapy for Cancer Pipeline Market | Page 5

8.12 GlaxoSmithKline plc. 8.13 Immunocore Ltd. 8.14 Cell Medica 8.15 Inovio Pharmaceuticals, Inc. List of Tables: Table 4-1: Global - Major Investments & Grants in T-Cell Immunotherapy (Million US$) Table 5-1: Global - Cancer Prevalence (Million), 2015 & 2025 Table 5-2: Global - Leukemia Prevalence ('000), 2015 & 2025 Table 5-3: North America - Leukemia Prevalence ('000), 2015 & 2025 Table 5-4: Europe - Leukemia Prevalence ('000), 2015 & 2025 Table 5-5: Asia-Pacific - Leukemia Prevalence ('000), 2015 & 2025 Table 5-6: Rest of the World - Leukemia Prevalence ('000), 2015 & 2025 Table 5-7: Global - Lymphoma Prevalence ('000), 2015 & 2025 Table 5-8: North America - Lymphoma Prevalence ('000), 2015 & 2025 Table 5-9: Europe - Lymphoma Prevalence ('000), 2015 & 2025 Table 5-10: Asia-Pacific - Lymphoma Prevalence ('000), 2015 & 2025 Table 5-11: Rest of the World - Lymphoma Prevalence ('000), 2015 & 2025 Table 5-12: Global - Multiple Myeloma Prevalence ('000), 2015 & 2025 Table 5-13: North America - Multiple Myeloma Prevalence ('000), 2015 & 2025 Table 5-14: Europe - Multiple Myeloma Prevalence ('000), 2015 & 2025 Table 5-15: Asia-Pacific - Multiple Myeloma Prevalence ('000), 2015 & 2025 Table 5-16: Rest of the World - Multiple Myeloma Prevalence ('000), 2015 & 2025 Table 5-17: Global - Melanoma Prevalence ('000), 2015 & 2025 Table 5-18: North America - Melanoma Prevalence ('000), 2015 & 2025 Table 5-19: Europe - Melanoma Prevalence ('000), 2015 & 2025 Follow Us: